The EIB has today taken a further step forward in fostering innovation in the Spanish and European pharmaceutical sector. By granting a EUR 120m loan to Almirall under the Investment Plan for Europe, the EU bank is financing research into new therapeutic indications for the benefit of patients with severe skin diseases for which there is currently no effective pharmaceutical treatment.  EIB Vice-President Emma Navarro, and Peter Guenter, CEO, Almirall, met today in Barcelona to sign the agreement.

Become a member of The Financial Analyst today. TFA publishes original opinion and news content on trending financial topics and breaking stories related to analysis and global markets. If you have a tip or a financial opinion to share get in touch to submit your story.

LEAVE A REPLY

Please enter your comment!
Please enter your name here